The path to a better biomarker: application of a risk management framework for the implementation of PD‐L1 and TILs as immuno‐oncology biomarkers in breast cancer clinical trials and daily practice
Paula I Gonzalez‐Ericsson,Elisabeth S Stovgaard,Luz F Sua,Emily Reisenbichler,Zuzana Kos,Jodi M Carter,Stefan Michiels,John Le Quesne,Torsten O Nielsen,Anne‐Vibeke Lænkholm,Stephen B Fox,Julien Adam,John MS Bartlett,David L Rimm,Cecily Quinn,Dieter Peeters,Maria V Dieci,Anne Vincent‐Salomon,Ian Cree,Akira I Hida,Justin M Balko,Harry R Haynes,Isabel Frahm,Gabriela Acosta‐Haab,Marcelo Balancin,Enrique Bellolio,Wentao Yang,Pawan Kirtani,Tomoharu Sugie,Anna Ehinger,Carlos A Castaneda,Marleen Kok,Heather McArthur,Kalliopi Siziopikou,Sunil Badve,Susan Fineberg,Allen Gown,Giuseppe Viale,Stuart J Schnitt,Giancarlo Pruneri,Frederique Penault‐Llorca,Stephen Hewitt,E Aubrey Thompson,Kimberly H Allison,William F Symmans,Andrew M Bellizzi,Edi Brogi,David A Moore,Denis Larsimont,Deborah A Dillon,Alexander Lazar,Huangchun Lien,Matthew P Goetz,Glenn Broeckx,Khalid El Bairi,Nadia Harbeck,Ashley Cimino‐Mathews,Christos Sotiriou,Sylvia Adams,Shi‐wei Liu,Sibylle Loibl,I‐Chun Chen,Sunil R Lakhani,Jonathan W Juco,Carsten Denkert,Elizabeth F Blackley,Sandra Demaria,Roberto Leon‐Ferre,Oleg Gluz,Dimitrios Zardavas,Kenneth Emancipator,Scott Ely,Sherene Loi,Roberto Salgado,Melinda Sanders,
DOI: https://doi.org/10.1002/path.5406
2020-04-01
The Journal of Pathology
Abstract:<p>Immune checkpoint inhibitor therapies targeting PD‐1/PD‐L1 are now standard of care in oncology across several hematologic and solid tumor types, including triple negative breast cancer (TNBC). Patients with metastatic or locally advanced TNBC with PD‐L1 expression on immune cells occupying ≥1% of tumor area demonstrated survival benefit with the addition of atezolizumab to nab‐paclitaxel. However, concerns regarding variability between immunohistochemical PD‐L1 assay performance and inter‐reader reproducibility have been raised. High tumor‐infiltrating lymphocytes (TILs) have also been associated with response to PD‐1/PD‐L1 inhibitors in patients with breast cancer. TILs can be easily assessed on hematoxylin and eosin stained slides and have shown reliable inter‐reader reproducibility. As an established prognostic factor in early stage TNBC, TILs are soon anticipated to be reported in daily practice in many pathology laboratories worldwide. Since TILs and PD‐L1 are parts of an immunological spectrum in breast cancer, we propose the systematic implementation of combined PD‐L1 and TIL analyses as a more comprehensive immune‐oncological biomarker for patient selection for PD‐1/PD‐L1 inhibition‐based therapy in patients with breast cancer. Although practical and regulatory considerations differ by jurisdiction, the pathology community has the responsibility to patients to implement assays that lead to optimal patient selection. We propose herewith a risk‐management framework that may help mitigate the risks of suboptimal patient selection for immuno‐therapeutic approaches in clinical trials and daily practice based on combined TILs/PD‐L1 assessment in breast cancer.</p><p>This article is protected by copyright. All rights reserved.</p>